Spike Protein News and Research

RSS

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A new study focused on in vitro antiviral activity in various cell models and in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Quantification of salivary IgG and IgA against SARS-CoV-2

Salivary antibody levels are many fold lower than found in blood serum, Immunoglobulin G (IgG) in the saliva is mainly sourced from leakage from the gingival surface and Immunoglobulin A (IgA) from mucosal membranes.

15 Sep 2021

New automated approach to detecting SARS-CoV-2 variants with increased growth rates

Researchers in the United States have developed a new automated approach to detecting variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that have increased growth rates over other lineages.

15 Sep 2021

Study reveals role of globalization and zoonosis in the emergence and spread of SARS-CoV-2 variants

A recent study aimed to use their own classification of different SARS-CoV-2 lineages that would help monitor their genetic features and geographical origins.

14 Sep 2021

Prior symptomatic COVID-19 enhances mRNA vaccine response

A new paper describes the antibody responses in people who have already been infected with SARS-CoV-2 and are vaccinated as compared to the naïve.

14 Sep 2021

Low dose of Moderna COVID-19 vaccine generates durable immune response

A new study from La Jolla Institute for Immunology (LJI) scientists helps answer the question: how long does immunity against COVID-19 last in vaccinated people?

14 Sep 2021

Study explains confounding effects of different dosages and dosing protocols on COVID-19 vaccine efficacies

A recent study investigates the paradoxical effects of dosage and dosing interval on COVID-19 vaccine efficacy.

14 Sep 2021

Severe COVID-19 linked to increase in autoantibodies

Hospitalized COVID-19 patients are substantially more likely to harbor autoantibodies -;antibodies directed at their own tissues or at substances their immune cells secrete into the blood -; than people without COVID-19, according to a new study.

14 Sep 2021

Impact of prior SARS-CoV-2 infection and vaccine on antibody levels: Texas survey

A collaborative team, led by principal investigator Dr. Eric Boerwinkle, at The University of Texas Health Science Center at Houston, School of Public Health is conducting a survey designed to assess the frequency of antibody-positive individuals across Texas. The TEXAS Coronavirus Antibody REsponse Survey (CARES) aims to look for antibodies in the blood made in response to natural SARS-CoV-2 infection or vaccination.

14 Sep 2021

Study identifies broadly neutralizing antibody panel against SARS-like viruses

A recent study describes 40 broadly neutralizing antibodies from two individuals with a history of COVID-19 who were recently immunized against the virus.

13 Sep 2021

RIT study uncovers new information about how coronavirus attaches itself to human cells

Rochester Institute of Technology scientists have uncovered new information about the way coronavirus and several of its variants attach to human cells.

13 Sep 2021

An oral COVID-19 vaccine induces mucosal and protective immunity

Researchers have collaborated to resolve the aforementioned problems associated with injection vaccines to create a thermostable vaccine that can be taken orally.

13 Sep 2021

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

A recent report published in the journal Cell Discovery has described the immunogenicity and protective efficacy of a novel coronavirus disease 2019 (COVID-19) subunit vaccine candidate. The vaccine induces robust immune responses in rodents and non-human primates and protects the animals against severe disease.

12 Sep 2021

The strengths and weaknesses of the spike protein in SARS-CoV-2 variants

The S protein has the ability to appropriate various conformations that are dependent on the formation of the receptor-binding domain (RBD) of its protomers.

12 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

A COVID-19 vaccine, created from a virus-like nanoparticle that displays SARS-CoV-2 spike protein RBDs, effectively protects animal model from infection.

10 Sep 2021

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.

8 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Researchers say modified COVID-19 vaccine boosters should control pandemic

Researchers in Texas have provided evidence for the need to modify the currently used coronavirus disease 2019 (COVID-19) vaccines to match circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Sep 2021

Spike Protein News and Research

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

Quantification of salivary IgG and IgA against SARS-CoV-2

New automated approach to detecting SARS-CoV-2 variants with increased growth rates

Study reveals role of globalization and zoonosis in the emergence and spread of SARS-CoV-2 variants

Prior symptomatic COVID-19 enhances mRNA vaccine response

Low dose of Moderna COVID-19 vaccine generates durable immune response

Study explains confounding effects of different dosages and dosing protocols on COVID-19 vaccine efficacies

Severe COVID-19 linked to increase in autoantibodies

Impact of prior SARS-CoV-2 infection and vaccine on antibody levels: Texas survey

Study identifies broadly neutralizing antibody panel against SARS-like viruses

RIT study uncovers new information about how coronavirus attaches itself to human cells

An oral COVID-19 vaccine induces mucosal and protective immunity

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

The strengths and weaknesses of the spike protein in SARS-CoV-2 variants

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers say modified COVID-19 vaccine boosters should control pandemic

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News